Sequent Scientific Limited
NSE: SEQUENT BSE: SEQUENT
Prev Close
192.63
Open Price
191.75
Volume
442,806
Today Low / High
187 / 193.15
52 WK Low / High
116.4 / 240.7
Range
178 - 197
Prev Close
192.25
Open Price
191.35
Volume
31,894
Today Low / High
187 / 193.15
52 WK Low / High
111 / 240.9
Range
178 - 197
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 187.85 (target range: 178 - 197), reflecting a change of -4.78 (-2.48144%). On the BSE, it is listed at 187.75 (target range: 178 - 197), showing a change of -4.5 (-2.3407%). The stock price is currently in decline on both exchanges, signaling a downtrend. If you're considering investing in this stock, it's important to monitor the situation closely.
Sequent Scientific Limited Graph
Sequent Scientific Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Sequent Scientific Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 187.85, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
Scenario | Price | Target | Range |
---|---|---|---|
Bullish Scenario | 187.75 | 189.63 | 170.66 - 208.59 |
191.51 | 153.20 - 229.81 | ||
193.38 | 135.37 - 251.40 | ||
Bearish Scenario | 187.75 | 185.87 | 167.29 - 204.46 |
184.00 | 147.20 - 220.79 | ||
182.12 | 127.48 - 236.75 |
Overview of Sequent Scientific Limited
ISIN
INE807F01027
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
908,700
Market Cap
47,019,230,700
Last Dividend
0
Official Website
IPO Date
2016-03-10
DCF Diff
191.17
DCF
-3
Financial Ratios Every Investor Needs
Stock Dividend of SEQUENT
Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
---|---|---|---|---|---|---|
2021-09-08 | September 08, 21 | 0.5 | 0.5 | 2021-09-10 | 2021-10-21 | |
2019-08-21 | August 21, 19 | 0.2 | 0.2 | 2019-08-22 | 2019-09-28 | 2019-05-14 |
2017-11-20 | November 20, 17 | 0.2 | 0.2 | 2017-11-21 | 2017-12-04 | 2017-11-09 |
Annual Financial Income Report
Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
---|---|---|---|---|---|---|---|---|---|---|---|
2024-03-31 | 1,366.30 Cr | 813.12 Cr | 553.19 Cr | 0.4049 | 0.00 Cr | 55.36 Cr | 37.02 Cr | -35.87 Cr | -1.44 | 54.98 Cr | -0.0263 |
2023-03-31 | 1,418.28 Cr | 1,259.55 Cr | 158.72 Cr | 0.1119 | 0.00 Cr | 54.03 Cr | -15.35 Cr | -121.16 Cr | -4.88 | -46.45 Cr | -0.0854 |
2022-03-31 | 1,410.17 Cr | 844.44 Cr | 565.74 Cr | 0.4012 | 0.00 Cr | 50.03 Cr | 67.40 Cr | 40.96 Cr | 1.65 | 117.98 Cr | 0.0290 |
2021-03-31 | 1,352.04 Cr | 736.56 Cr | 615.47 Cr | 0.4552 | 0.00 Cr | 45.51 Cr | 175.22 Cr | 95.44 Cr | 3.87 | 206.48 Cr | 0.0706 |
2020-03-31 | 1,160.51 Cr | 638.41 Cr | 522.10 Cr | 0.4499 | 0.00 Cr | 38.05 Cr | 145.82 Cr | 69.91 Cr | 2.87 | 177.40 Cr | 0.0602 |
Annual Financials Balance Sheet
Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
---|---|---|---|---|---|---|---|---|---|---|---|---|
2024-03-31 | 64.81 Cr | 1,540.38 Cr | 827.43 Cr | 656.5600 Cr | 487.69 Cr | 422.88 Cr | 346.23 Cr | 311.23 Cr | 8.13 Cr | 0.00 Cr | 0.01 Cr | 626.9900 Cr |
2023-03-31 | 41.57 Cr | 1,529.12 Cr | 779.93 Cr | 698.7780 Cr | 443.60 Cr | 402.02 Cr | 346.09 Cr | 352.13 Cr | -0.56 Cr | 0.00 Cr | 0.01 Cr | 558.7580 Cr |
2022-03-31 | 57.50 Cr | 1,450.97 Cr | 710.87 Cr | 692.0982 Cr | 364.90 Cr | 307.40 Cr | 347.97 Cr | 325.34 Cr | 3.36 Cr | 0.00 Cr | 36.79 Cr | 512.1210 Cr |
2021-03-31 | 53.74 Cr | 1,392.56 Cr | 616.24 Cr | 727.6510 Cr | 276.98 Cr | 223.24 Cr | 264.36 Cr | 347.86 Cr | 0.00 Cr | 0.00 Cr | 76.94 Cr | 460.0170 Cr |
2020-03-31 | 68.10 Cr | 1,462.65 Cr | 730.81 Cr | 687.1040 Cr | 404.13 Cr | 336.04 Cr | 219.42 Cr | 355.95 Cr | 6.52 Cr | 8.03 Cr | 131.29 Cr | 494.6990 Cr |
Annual Financials Cash Flow Statement
Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
---|---|---|---|---|---|---|---|---|---|---|---|
2024-03-31 | 30.5950 Cr | -11.9050 Cr | 4.5460 Cr | -0.2120 Cr | 23.2360 Cr | 64.8100 Cr | -30.8070 Cr | -35.8690 Cr | 54.8070 Cr | 0.0000 Cr | 0.2860 Cr |
2023-03-31 | 16.8080 Cr | -64.9580 Cr | 32.2280 Cr | -69.3710 Cr | -15.9220 Cr | 41.5740 Cr | -86.1790 Cr | -137.6580 Cr | 12.3490 Cr | 0.0000 Cr | 5.0790 Cr |
2022-03-31 | 30.5950 Cr | -95.5660 Cr | 67.2570 Cr | -1.8690 Cr | 3.7520 Cr | 57.4960 Cr | -32.4640 Cr | 52.9300 Cr | 91.1120 Cr | -12.3440 Cr | -114.7330 Cr |
2021-03-31 | 114.7540 Cr | 9.6480 Cr | -138.7540 Cr | 61.9240 Cr | -14.3520 Cr | 53.7440 Cr | -52.8300 Cr | 145.4520 Cr | -117.4150 Cr | 0.0000 Cr | -45.6170 Cr |
2020-03-31 | 115.3300 Cr | -72.2700 Cr | -42.7530 Cr | 74.6080 Cr | 0.3070 Cr | 68.0960 Cr | -40.7220 Cr | 94.0750 Cr | -6.7720 Cr | -5.8260 Cr | -19.3140 Cr |
Quarterly Financial Income Report
Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
---|---|---|---|---|---|---|---|---|---|
2024-12-31 | 390.81 Cr | 202.53 Cr | 188.28 Cr | 0.4818 | 16.98 Cr | 3.44 Cr | 0.14 | 40.03 Cr | 0.0088 |
2024-09-30 | 368.65 Cr | 195.29 Cr | 173.36 Cr | 0.4703 | 19.47 Cr | 2.61 Cr | 0.11 | 39.29 Cr | 0.0071 |
2024-06-30 | 390.21 Cr | 214.29 Cr | 175.92 Cr | 0.4508 | 113.87 Cr | 6.51 Cr | 0.26 | 44.63 Cr | 0.0167 |
2024-03-31 | 361.20 Cr | 273.21 Cr | 87.99 Cr | 0.2436 | 17.77 Cr | -0.91 Cr | -0.04 | 31.56 Cr | -0.0025 |
2023-12-31 | 329.36 Cr | 253.95 Cr | 75.41 Cr | 0.2290 | 7.44 Cr | 8.27 Cr | 0.33 | 29.53 Cr | 0.0251 |
Quarterly Financials Balance Sheet
Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
---|---|---|---|---|---|---|---|---|---|
2024-09-30 | 68.05 Cr | 7.38 Cr | 75.43 Cr | 0.00 Cr | 361.48 Cr | 828.95 Cr | 306.00 Cr | 1,562.05 Cr | 820.18 Cr |
2024-06-30 | 0.00 Cr | 0.00 Cr | 72.44 Cr | 0.00 Cr | 0.00 Cr | 72.44 Cr | 0.00 Cr | 0.00 Cr | -712.96 Cr |
2024-03-31 | 64.81 Cr | 3.98 Cr | 68.79 Cr | 335.63 Cr | 346.23 Cr | 822.86 Cr | 311.23 Cr | 1,540.38 Cr | 827.43 Cr |
2023-12-31 | -59.88 Cr | 119.76 Cr | 59.88 Cr | 0.00 Cr | 0.00 Cr | 59.88 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
2023-09-30 | 58.86 Cr | 2.96 Cr | 61.82 Cr | 309.46 Cr | 326.17 Cr | 772.89 Cr | 335.51 Cr | 1,500.95 Cr | 818.29 Cr |
Quarterly Financials Cash Flow Statement
Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
---|---|---|---|---|---|---|---|---|---|
2024-06-30 | 6.51 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
2024-03-31 | -0.91 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
2023-12-31 | 8.27 Cr | 30.91 Cr | 0.00 Cr | 0.00 Cr | 30.91 Cr | 89.84 Cr | 58.93 Cr | 0.00 Cr | 30.91 Cr |
2023-09-30 | -8.38 Cr | 30.72 Cr | 0.00 Cr | 0.00 Cr | 30.72 Cr | 58.93 Cr | 28.21 Cr | 0.00 Cr | 30.72 Cr |
2023-06-30 | -34.85 Cr | 28.48 Cr | 0.00 Cr | 0.00 Cr | 28.48 Cr | 70.23 Cr | 41.75 Cr | 0.00 Cr | 28.48 Cr |
Splits History
Date | Label | Split Ratio |
---|---|---|
No split history data available. |
Similar Stocks: Drug Manufacturers - Specialty & Generic
Company Name | Symbol | Price | Market Cap | Volume |
---|---|---|---|---|
Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,679.20 | ₹4,028,870,976,000.00 | ₹2,500,031.00 |
Divi's Laboratories Limited | DIVISLAB | ₹6,544.50 | ₹1,737,361,870,500.00 | ₹361,018.00 |
Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,320.90 | ₹1,100,458,988,118.00 | ₹2,158,463.00 |
Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,154.30 | ₹1,067,557,063,500.00 | ₹86,576.00 |
Mankind Pharma Limited | MANKIND | ₹2,352.40 | ₹970,767,378,020.00 | ₹353,197.00 |
Zydus Lifesciences Limited | ZYDUSLIFE | ₹960.15 | ₹966,131,734,500.00 | ₹810,089.00 |
Lupin Limited | LUPIN | ₹1,999.60 | ₹913,207,322,000.00 | ₹1,289,535.00 |
Aurobindo Pharma Limited | AUROPHARMA | ₹1,161.10 | ₹674,369,202,200.00 | ₹392,642.00 |
Alkem Laboratories Limited | ALKEM | ₹4,862.50 | ₹581,384,812,500.00 | ₹181,782.00 |
Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,590.20 | ₹448,756,030,200.00 | ₹940,265.00 |
Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
Cohance Lifesciences Limited | COHANCE | ₹1,055.10 | ₹403,646,450,141.00 | ₹209,681.00 |
Ipca Laboratories Limited | IPCALAB | ₹1,370.90 | ₹347,802,813,600.00 | ₹594,702.00 |
Laurus Labs Limited | LAURUSLABS | ₹642.05 | ₹346,227,388,650.00 | ₹1,658,718.00 |
Ajanta Pharma Limited | AJANTPHARM | ₹2,571.30 | ₹321,186,225,600.00 | ₹84,218.00 |
Piramal Enterprises Limited | PEL | ₹1,173.70 | ₹266,051,968,600.00 | ₹1,087,297.00 |
J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,702.30 | ₹265,322,180,300.00 | ₹62,791.00 |
AstraZeneca Pharma India Limited | ASTRAZEN | ₹9,790.00 | ₹244,750,000,000.00 | ₹123,199.00 |
Wockhardt Limited | WOCKPHARMA | ₹1,505.40 | ₹244,595,886,600.00 | ₹803,276.00 |
Eris Lifesciences Limited | ERIS | ₹1,638.30 | ₹223,111,885,500.00 | ₹55,563.00 |
Alembic Pharmaceuticals Limited | APLLTD | ₹987.60 | ₹194,125,618,800.00 | ₹40,498.00 |
Jubilant Pharmova Limited | JUBLPHARMA | ₹1,140.00 | ₹181,580,340,000.00 | ₹116,733.00 |
Neuland Laboratories Limited | NEULANDLAB | ₹13,030.00 | ₹167,173,597,000.00 | ₹539,376.00 |
Caplin Point Laboratories Limited | CAPLIPOINT | ₹2,093.30 | ₹159,115,291,610.00 | ₹64,315.00 |
NATCO Pharma Limited | NATCOPHARM | ₹858.30 | ₹153,730,113,000.00 | ₹354,578.00 |
Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
Granules India Limited | GRANULES | ₹529.95 | ₹128,536,192,800.00 | ₹485,798.00 |
Procter & Gamble Health Limited | PGHL | ₹5,560.50 | ₹92,300,963,700.00 | ₹8,096.00 |
Shilpa Medicare Limited | SHILPAMED | ₹914.45 | ₹89,424,888,505.00 | ₹310,698.00 |
Aarti Pharmalabs Limited | AARTIPHARM | ₹909.25 | ₹82,409,528,235.00 | ₹242,116.00 |
Strides Pharma Science Limited | STAR | ₹782.30 | ₹72,098,880,210.00 | ₹430,298.00 |
FDC Limited | FDC | ₹429.20 | ₹69,878,052,000.00 | ₹308,089.00 |
Sun Pharma Advanced Research Company Limited | SPARC | ₹165.55 | ₹53,724,617,100.00 | ₹2,347,837.00 |
Innova Captab Limited | INNOVACAP | ₹889.10 | ₹50,878,685,263.00 | ₹72,505.00 |
Suven Life Sciences Limited | SUVEN | ₹221.19 | ₹48,235,788,060.00 | ₹1,475,325.00 |
Sequent Scientific Limited | SEQUENT | ₹187.85 | ₹47,019,230,700.00 | ₹442,806.00 |
Hikal Limited | HIKAL | ₹372.35 | ₹45,911,127,350.00 | ₹154,610.00 |
Aarti Drugs Limited | AARTIDRUGS | ₹462.15 | ₹42,180,430,500.00 | ₹112,178.00 |
Unichem Laboratories Limited | UNICHEMLAB | ₹592.90 | ₹41,743,598,820.00 | ₹18,878.00 |
Gufic Biosciences Limited | GUFICBIO | ₹368.10 | ₹36,912,331,800.00 | ₹50,918.00 |
Orchid Pharma Limited | ORCHPHARMA | ₹718.15 | ₹36,423,921,665.00 | ₹149,821.00 |
RPG Life Sciences Limited | RPGLIFE | ₹2,141.70 | ₹35,421,576,300.00 | ₹12,390.00 |
Morepen Laboratories Limited | MOREPENLAB | ₹64.12 | ₹35,134,810,480.00 | ₹2,840,731.00 |
Alembic Limited | ALEMBICLTD | ₹112.07 | ₹28,777,558,628.00 | ₹591,652.00 |
IOL Chemicals and Pharmaceuticals Limited | IOLCP | ₹88.74 | ₹26,047,585,980.00 | ₹1,118,303.00 |
Indoco Remedies Limited | INDOCO | ₹275.10 | ₹25,377,397,290.00 | ₹25,198.00 |
Key Executives
Gender: male
Year Born:
Gender: male
Year Born:
Gender: male
Year Born:
Gender: male
Year Born: 1968
Gender: male
Year Born:
Gender: female
Year Born:
Gender: male
Year Born: 1965
Gender: male
Year Born:
Gender: male
Year Born:
FAQs about Sequent Scientific Limited
The CEO is Mr. Rajaram Narayanan.
The current price is ₹187.85.
The range is ₹116.4-240.7.
The market capitalization is ₹4,701.92 crores.
The P/E ratio is 396.24.
The company operates in the Healthcare sector.
Overview of Sequent Scientific Limited (ISIN: INE807F01027) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹4,701.92 crores and an average daily volume of 908,700 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹0.